Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 244 matching trials from the live ClinicalTrials.gov search.
Conditions
Behavior Therapy, Cocaine, Contingency Management, Heroin Dependence, LAAM, Opioid Dependence, Substance-Related Disorders, Alcohol & Drug Use
Interventions
LAAM
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Heroin Dependence, Opiate Dependence, Substance Dependence
Interventions
CRAFT-T, Treatment as usual
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Opioid Use Disorder
Interventions
Intravenous Challenge Drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky • New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers

Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1

NCT00023283
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions
Buprenorphine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Medication Development for Opioid and Alcohol Abuse

NCT03205423
Conditions
Opioid-use Disorder, Alcohol Use Disorder
Interventions
Gabapentin
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Trial of Adherence App for Buprenorphine Treatment (TAAB) Study

NCT03779997
Conditions
Opioid-Related Disorders
Interventions
Video-based DOT Application
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Conditions
Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
Interventions
Observation Only
Other
Lead sponsor
Member Companies of the Opioid PMR Consortium
Industry
Eligibility
18 Years to 79 Years
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Medication-based Analgesia in Humans

NCT02901275
Conditions
Pain, Cannabis, Opioid Use, Unspecified
Interventions
Within-subject test of blinded study medications
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 2 Interventional Results available

Evaluation of Doxazosin to Alter the Abuse of Oxycodone

NCT03415581
Conditions
Opioid-use Disorder
Interventions
Intranasal Oxycodone, Cue Session
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Manhattan, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Cebranopadol in Humans

NCT05256108
Conditions
Human Abuse Potential
Interventions
Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Compliance, Chronic Pain
Interventions
acetazolamide, Quinine, Riboflavin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Arthropathy of Knee, Post Operative Pain, Opioid Use, Opioid Abuse, Opioid Misuse
Interventions
Opioid education in person, Opioid education via video
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

An Opioid Prescribing Nudge

NCT04069403
Conditions
Opioid Use, Unspecified, Prescription Drug Abuse (Not Dependent), Prescription Drug Abuse and Dependency, Health Behavior, Benzodiazepine Abuse, Benzodiazepine Dependent
Interventions
Automated Reports on prescription patterns for their patients
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Opioid Use, Opioid Abuse
Interventions
Sociobehavioral Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Opioid-Related Disorders, Chronic Pain
Interventions
Buprenorphine, Hydromorphone, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Opioid-use Disorder, Opioid Dependence, Opioid Abuse
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Opioid Use, Opioid-Related Disorders, Opioid Abuse, Prescription Drug Abuse and Dependency
Interventions
Default Prescribing Change
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
948 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York
Conditions
Substance-Related Disorders, Substance Use Disorders, Substance Abuse, Intravenous, Substance Withdrawal, Substance Abuse, Opioid-use Disorder, Opioid Use Disorder, Severe, Opioid Use
Interventions
Non invasive VN stimulation (nVNS), Oxygen (15-O) Water, Sham Stimulation
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
ADHD, Stimulant-Induced Euphoria
Interventions
SODAS MPH, Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Post Traumatic Stress Disorder, Alcohol Abuse
Interventions
2mg Buprenex and 380mg Vivitrol, Placebo (SL pill qd, IM injection q4weeks)
Drug
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama • West Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nudges and Incentives to Enhance the Opioid Treatment Workforce

NCT03834025
Conditions
Opioid Abuse (Disorder)
Interventions
Phase 1 Condition 1, Phase 1 Condition 2, Phase 1 Condition 3, Phase 1 Condition 4, Phase 2 Condition 1, Phase 2 Condition 2, Phase 2 Condition 3
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed No phase listed Observational Accepts healthy volunteers Results available

Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool

NCT03936985
Conditions
Opioid Abuse, Prescription Drug Abuse (Not Dependent)
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,464 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • Salt Lake City, Utah